Trazodone Primary Indications and Uses
Trazodone is FDA-approved solely for the treatment of major depressive disorder (MDD) in adults, but is predominantly prescribed off-label for insomnia, with approximately 85% of prescriptions written for non-approved indications 1, 2.
FDA-Approved Indication
The only official indication for trazodone is major depressive disorder in adults 1. The medication is not approved for use in children, and its safety and efficacy in pediatric populations remain unestablished 1.
Off-Label Uses
Insomnia (Most Common Off-Label Use)
Trazodone demonstrates sedative effects at low doses (25-75 mg), making it the most frequently prescribed off-label indication 3. However, VA/DoD guidelines from 2020 explicitly recommend AGAINST using trazodone for chronic insomnia disorder 4. This recommendation stems from:
- Low-quality evidence supporting efficacy
- No differences in sleep efficiency or discontinuation rates versus placebo
- Adverse effect profile outweighing benefits
- Studies showing only subjective sleep quality improvement without objective measures (sleep onset latency, total sleep time, wake after sleep onset) 4
Despite these guideline recommendations against its use, trazodone remains widely prescribed for insomnia, representing a significant evidence-practice gap 2.
Depression-Related Uses
The 2022 VA/DoD guidelines for major depressive disorder now include trazodone with a higher-level recommendation compared to the 2016 version, particularly for MDD that is severe or has partial/limited response to initial treatment 5. This represents an upgrade in the strength of recommendation based on updated evidence.
Other Off-Label Uses
Evidence exists (though variable in quality) for trazodone use in:
- Anxiety disorders (generalized anxiety disorder, panic disorder, PTSD, OCD) 6, 7, 8
- Behavioral disturbances in dementia and other neurodegenerative conditions 9
- Adjunctive therapy with SSRIs to prevent or treat SSRI-induced side effects (anxiety, insomnia, sexual dysfunction) 7, 8
- Substance use disorders (benzodiazepine/alcohol dependence) 6, 7
- Chronic pain conditions and diabetic neuropathy 6, 7
- Eating disorders (bulimia) 6, 7
Dosing Considerations
Trazodone exhibits dose-dependent effects 3:
- 25-75 mg: Sedative and anxiolytic effects
- 150-300 mg: Full antidepressant effects
The medication should be taken shortly after a meal or light snack 1.
Critical Safety Considerations
Absolute Contraindications
- Concurrent use with MAOIs or within 14 days of MAOI discontinuation due to serotonin syndrome risk 1
- This includes linezolid and intravenous methylene blue 1
Important Warnings
- Black box warning for suicidal thoughts/actions in children, teenagers, and young adults, particularly in the first few months of treatment 1
- Requires monitoring for mood changes, especially when starting or changing doses 1
Clinical Reality vs. Evidence
A major disconnect exists between clinical practice and evidence-based recommendations: approximately 24 million trazodone prescriptions were filled in 2019 in the United States, with 85% for off-label indications (primarily insomnia), totaling $247 million in spending 2. This occurs despite guidelines recommending against its use for insomnia and limited high-quality evidence for many off-label applications 4, 2.
Large, randomized controlled trials are still needed to confirm efficacy for most conditions where trazodone is commonly prescribed in clinical practice 6, 7, 8.